国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
21期
2637-2639
,共3页
益赛普%柳氮黄砒碇%强直性脊柱炎%治疗%研究
益賽普%柳氮黃砒碇%彊直性脊柱炎%治療%研究
익새보%류담황비정%강직성척주염%치료%연구
Etanercept%Sulfasalazine%Ankylosing spondylitis%Treatment%Study
目的 通过与柳氮磺砒啶(SSZ)进行对照,研究益赛普对强直性脊柱炎(AS)的疗效.方法 选取处于活动期的AS患者40例,分别给予益赛普(50 mg/周)及柳氮磺砒碇(2.0g/日)进行治疗,总疗程为24周,对两药在12、24周时疗效及观察指标进行评估.结果 益赛普在12、24周时的有效率分别为90.0%,95.0%,柳氮磺吡啶都为70.0%.显示益赛普能显著改善临床实验观察指标(P<0.05),耐受性与柳氮磺吡啶差异无显著性(P>0.5). 结论益赛普是一种新型有效且安全的治疗AS的药物.
目的 通過與柳氮磺砒啶(SSZ)進行對照,研究益賽普對彊直性脊柱炎(AS)的療效.方法 選取處于活動期的AS患者40例,分彆給予益賽普(50 mg/週)及柳氮磺砒碇(2.0g/日)進行治療,總療程為24週,對兩藥在12、24週時療效及觀察指標進行評估.結果 益賽普在12、24週時的有效率分彆為90.0%,95.0%,柳氮磺吡啶都為70.0%.顯示益賽普能顯著改善臨床實驗觀察指標(P<0.05),耐受性與柳氮磺吡啶差異無顯著性(P>0.5). 結論益賽普是一種新型有效且安全的治療AS的藥物.
목적 통과여류담광비정(SSZ)진행대조,연구익새보대강직성척주염(AS)적료효.방법 선취처우활동기적AS환자40례,분별급여익새보(50 mg/주)급류담광비정(2.0g/일)진행치료,총료정위24주,대량약재12、24주시료효급관찰지표진행평고.결과 익새보재12、24주시적유효솔분별위90.0%,95.0%,류담광필정도위70.0%.현시익새보능현저개선림상실험관찰지표(P<0.05),내수성여류담광필정차이무현저성(P>0.5). 결론익새보시일충신형유효차안전적치료AS적약물.
Objective To explore the efficacy of etanercept for ankylosiong spondylitis ( AS ) by comparing with sulfasalazine. Methods 40 patients with active AS were randomly assigned to receive etanercept ( 50mg weekly ) or sulfasalazine ( 2.0g daily ) for 24weeks. Efficacy was assessed at weeks 12 and 24 in both groups. Results The effectiveness rate ofetanercept was 90% at week 12 and 95% at week 24,while sulfasalazine was 70% at weeks 12 and 24. Etanercept was similar with sulfasalazine in drug tolerance.Conclusions Etanercept is a new effecitve and more safe drug.
